Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients
with Plasma Cell Disorders: A Potential New Diagnostic Marker
and a New Therapeutic Target?

J 2019

Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?

STEINER, N., Roman HÁJEK, D. NACHBAUR, B. BORJAN, Sabina ŠEVČÍKOVÁ et. al.

Basic information

Original name

Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?

Authors

STEINER, N. (40 Austria, guarantor), Roman HÁJEK (203 Czech Republic), D. NACHBAUR (40 Austria), B. BORJAN (40 Austria), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), G. GOBEL (40 Austria) and E. GUNSILIUS (40 Austria)

Edition

Disease Markers, London, Hindawi Publishing Corporation, 2019, 0278-0240

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.738

RIV identification code

RIV/00216224:14110/19:00109469

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1155/2019/1806034

UT WoS

000458397800001

Keywords in English

CEACAM6

Abstract

V originále

Introduction. The prognosis of multiple myeloma is still unfavorable due to inherent characteristics of the disease and the often-delayed diagnosis due to widespread and unspecific symptoms such as back pain and fatigue. Therefore, a simple diagnostic blood test would be helpful to speed up the diagnostic procedure in such patients (pts.). Here, we evaluated the diagnostic value of plasma levels of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in the peripheral blood and bone marrow of pts. with plasma cell disorders and in healthy controls. Materials and Methods. Immunoreactive CEACAM6 was determined in the peripheral blood and bone marrow (n=95/100) of pts. with monoclonal gammopathy of unknown significance (MGUS: 28/37), newly diagnosed multiple myeloma (NDMM: 42/40), and relapsed/refractory multiple myeloma (RRMM: 25/23) by sandwich ELISA. Results. Median CEACAM6 levels in the peripheral blood of pts. with plasma cell disorders were significantly higher than those of healthy controls (healthy controls: 15.2pg/ml (12.1-17.1); MGUS: 19.0pg/ml (16.4-22.5); NDMM: 18.0pg/ml (13.4-21.2); and RRMM: 18.9pg/ml (15.2-21.5); p<0.001). Plasma levels of CEACAM6 discriminated healthy subjects from MGUS/NDMM pts. (AUC=0.71, 95% CI: 0.6-0.8); i.e., a CEACAM6 level>17.3pg/ml has an 82% (95% CI: 70-90) predictive probability for the identification of MGUS or NDMM. Moreover, CEACAM6 levels in the bone marrow were significantly higher in RRMM pts. than in NDMM pts. (p=0.04), suggesting a role of this molecule in disease progression. Conclusion. CEACAM6 plasma levels can noninvasively identify pts. with a plasma cell disorder and should be evaluated prospectively as a potential diagnostic marker. Moreover, due to high CEACAM6 levels in the bone marrow in RRMM pts., this adhesion molecule might be a therapeutic target in multiple myeloma pts.

Links

MUNI/A/1553/2018, interní kód MU

Name: Genetické, environmentální a tkáňové charakteristiky vybraných patologických stavů a nemocí (Acronym: genetika; stres; biomateriály; tkáňové kultury)

Investor: Masaryk University, Category A

Citovat

STEINER, N., Roman HÁJEK, D. NACHBAUR, B. BORJAN, Sabina ŠEVČÍKOVÁ, G. GOBEL and E. GUNSILIUS. Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target? Disease Markers. London: Hindawi Publishing Corporation, 2019, vol. 2019, No 1806034, p. 1-6. ISSN 0278-0240. Available from: https://dx.doi.org/10.1155/2019/1806034.

@article{1521756,
   author = {Steiner, N. and Hájek, Roman and Nachbaur, D. and Borjan, B. and Ševčíková, Sabina and Gobel, G. and Gunsilius, E.},
   article_location = {London},
   article_number = {1806034},
   doi = {http://dx.doi.org/10.1155/2019/1806034},
   keywords = {CEACAM6},
   language = {eng},
   issn = {0278-0240},
   journal = {Disease Markers},
   title = {Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?},
   url = {http://dx.doi.org/10.1155/2019/1806034},
   volume = {2019},
   year = {2019}
}

TY  - JOUR
ID  - 1521756
AU  - Steiner, N. - Hájek, Roman - Nachbaur, D. - Borjan, B. - Ševčíková, Sabina - Gobel, G. - Gunsilius, E.
PY  - 2019
TI  - Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?
JF  - Disease Markers
VL  - 2019
IS  - 1806034
SP  - 1-6
EP  - 1-6
PB  - Hindawi Publishing Corporation
SN  - 02780240
KW  - CEACAM6
UR  - http://dx.doi.org/10.1155/2019/1806034
L2  - http://dx.doi.org/10.1155/2019/1806034
N2  - Introduction. The prognosis of multiple myeloma is still unfavorable due to inherent characteristics of the disease and the often-delayed diagnosis due to widespread and unspecific symptoms such as back pain and fatigue. Therefore, a simple diagnostic blood test would be helpful to speed up the diagnostic procedure in such patients (pts.). Here, we evaluated the diagnostic value of plasma levels of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in the peripheral blood and bone marrow of pts. with plasma cell disorders and in healthy controls. Materials and Methods. Immunoreactive CEACAM6 was determined in the peripheral blood and bone marrow (n=95/100) of pts. with monoclonal gammopathy of unknown significance (MGUS: 28/37), newly diagnosed multiple myeloma (NDMM: 42/40), and relapsed/refractory multiple myeloma (RRMM: 25/23) by sandwich ELISA. Results. Median CEACAM6 levels in the peripheral blood of pts. with plasma cell disorders were significantly higher than those of healthy controls (healthy controls: 15.2pg/ml (12.1-17.1); MGUS: 19.0pg/ml (16.4-22.5); NDMM: 18.0pg/ml (13.4-21.2); and RRMM: 18.9pg/ml (15.2-21.5); p<0.001). Plasma levels of CEACAM6 discriminated healthy subjects from MGUS/NDMM pts. (AUC=0.71, 95% CI: 0.6-0.8); i.e., a CEACAM6 level>17.3pg/ml has an 82% (95% CI: 70-90) predictive probability for the identification of MGUS or NDMM. Moreover, CEACAM6 levels in the bone marrow were significantly higher in RRMM pts. than in NDMM pts. (p=0.04), suggesting a role of this molecule in disease progression. Conclusion. CEACAM6 plasma levels can noninvasively identify pts. with a plasma cell disorder and should be evaluated prospectively as a potential diagnostic marker. Moreover, due to high CEACAM6 levels in the bone marrow in RRMM pts., this adhesion molecule might be a therapeutic target in multiple myeloma pts.
ER  -

STEINER, N., Roman HÁJEK, D. NACHBAUR, B. BORJAN, Sabina ŠEVČÍKOVÁ, G. GOBEL and E. GUNSILIUS. Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target? \textit{Disease Markers}. London: Hindawi Publishing Corporation, 2019, vol.~2019, No~1806034, p.~1-6. ISSN~0278-0240. Available from: https://dx.doi.org/10.1155/2019/1806034.

Detailed Information on Publication Record